Recent Advances in SARS-CoV-2 Main Protease Inhibitors: From Nirmatrelvir to Future Perspectives-Reference-Cited by-同舟云学术

Recent Advances in SARS-CoV-2 Main Protease Inhibitors: From Nirmatrelvir to Future Perspectives

Published:2023-09-02 Issue:9 Volume:13 Page:1339
ISSN:2218-273X
Container-title:Biomolecules
language:en
Short-container-title:Biomolecules

Author:

Citarella Andrea¹^ORCID,Dimasi Alessandro¹,Moi Davide²^ORCID,Passarella Daniele¹^ORCID,Scala Angela³^ORCID,Piperno Anna³^ORCID,Micale Nicola³^ORCID

Affiliation:

1. Department of Chemistry, University of Milan, Via Golgi 19, 20133 Milano, Italy

2. Department of Chemical and Geological Sciences, University of Cagliari, S.P. 8 CA, 09042 Cagliari, Italy

3. Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D’Alcontres 31, 98166 Messina, Italy

Abstract

The main protease (Mpro) plays a pivotal role in the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and is considered a highly conserved viral target. Disruption of the catalytic activity of Mpro produces a detrimental effect on the course of the infection, making this target one of the most attractive for the treatment of COVID-19. The current success of the SARS-CoV-2 Mpro inhibitor Nirmatrelvir, the first oral drug for the treatment of severe forms of COVID-19, has further focused the attention of researchers on this important viral target, making the search for new Mpro inhibitors a thriving and exciting field for the development of antiviral drugs active against SARS-CoV-2 and related coronaviruses.

Funder

FFABR_PA_MICALE_NICOLA_ATENEO_2022

Publisher

MDPI AG

Subject

Molecular Biology,Biochemistry

Link

https://www.mdpi.com/2218-273X/13/9/1339/pdf

Reference124 articles.

1. Accelerating Antiviral Drug Discovery: Lessons from COVID-19;Hall;Nat. Rev. Drug Discov.,2023

2. Citarella, A., Scala, A., Piperno, A., and Micale, N. (2021). SARS-CoV-2 Mpro: A Potential Target for Peptidomimetics and Small-Molecule Inhibitors. Biomolecules, 11.

3. COVID-19: Pfizer’s Paxlovid Is 89% Effective in Patients at Risk of Serious Illness, Company Reports;Mahase;BMJ,2021

4. A Patent Review on SARS Coronavirus Main Protease (3CL pro) Inhibitors;Chia;ChemMedChem,2022

5. Protease Inhibitors Targeting the Main Protease and Papain-like Protease of Coronaviruses;Capasso;Expert Opin. Ther. Pat.,2021

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, synthesis, and biological evaluation of first-in-class indomethacin-based PROTACs degrading SARS-CoV-2 main protease and with broad-spectrum antiviral activity;European Journal of Medicinal Chemistry;2024-02

2. Discovery of α-Ketoamide inhibitors of SARS-CoV-2 main protease derived from quaternized P1 groups;Bioorganic Chemistry;2024-02

3. Exploiting high-energy hydration sites for the discovery of potent peptide aldehyde inhibitors of the SARS-CoV-2 main protease with cellular antiviral activity;Bioorganic & Medicinal Chemistry;2024-01

4. Design, Synthesis, and Biological Evaluation of Trisubstituted Piperazine Derivatives as Noncovalent Severe Acute Respiratory Syndrome Coronavirus 2 Main Protease Inhibitors with Improved Antiviral Activity and Favorable Druggability;Journal of Medicinal Chemistry;2023-11-22